The interleukin-6 inhibitor tocilizumab may improve systemic symptoms and reduce the need for glucocorticoids among patients with adult-onset Still’s disease refractory to glucocorticoid therapy, suggest findings from a small randomized trial.
Ann Rheum Dis 2018; doi:10.1136/annrheumdis-2018-213920
Response to canakinumab therapy is sustained or even improved for up to 5 years in children with systemic juvenile idiopathic arthritis, with no new safety signals, according to the results of a long-term extension study published in the Annals of the Rheumatic Diseases.
Ann Rheum Dis 2018; doi:10.1136/annrheumdis-2018-213150
In this medwireNews podcast, we talk to Editorial Board member Sangeeta Sule about how patients with juvenile arthritis transition from pediatric to adult care, the challenges associated with this transition, and how the process can be improved.
Douglas Veale comments on study results showing that secukinumab-treated PsA patients have low rates of radiographic progression regardless of prior TNF inhibitor exposure or concomitant methotrexate treatment (2:45).